1. No category

Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG
Alcon receives FDA approval of Pazeo™ Solution for ocular allergy
itch relief

US Food and Drug Administration grants approval of Pazeo™ (olopatadine
hydrochloride ophthalmic solution) 0.7% for sale in the United States

Developed with efficacy data at 24 hours, post dose, to provide one-drop daily
ocular itch relief associated with allergic conjunctivitis (eye allergies)

Up to 30% of the U.S. population is affected by seasonal allergy symptoms, with
as many as 70 to 80% of these demonstrating ocular symptoms such as itching1
Basel, February 2, 2015 – Alcon, the global leader in eye care and a division of
Novartis, has received approval from the US Food and Drug Administration (FDA) of
Pazeo™ (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of
ocular itching associated with allergic conjunctivitis. Pazeo solution is dosed one drop
daily, and was approved with efficacy data at 24 hours, post dose.
“Pazeo solution represents an important addition to our ocular allergy portfolio in the
United States,” said Sabri Markabi, Senior Vice President, Research & Development for
Alcon. “Patients who experience itching due to allergic conjunctivitis (eye allergies), will
now be able to turn to a one-drop daily product with efficacy data 24 hours after dosing.”
As much as 30% of the U.S. population is affected by seasonal allergy symptoms, and
up to 70 to 80% of these demonstrate ocular symptoms such as itchy eyes.1
Results from two Conjunctival Allergen Challenge clinical studies showed that Pazeo
(olopatadine hydrochloride ophthalmic solution) 0.7%, demonstrated statistically
significantly improved relief of ocular itching associated with allergic conjunctivitis at 24
hours post-treatment compared to olopatadine 0.2% (known as Pataday® solution).* The
safety profile of Pazeo solution is comparable to that of olopatadine 0.2%. In the two
clinical studies, the most common adverse reactions occurred in 2 to 5% of patients
treated with either Pazeo solution or a vehicle. These events were blurred vision, dry
eye, superficial punctate keratitis, dysgeusia and abnormal sensation in the eye.
“Allergic conjunctivitis (eye allergies) can be a 24-hour-a-day burden for patients
suffering from those symptoms,” said Eric Donnenfeld, MD, founding partner of
Ophthalmic Consultants of Long Island and clinical professor of ophthalmology at New
York University. “Patients now have an available option that can provide ocular itch relief
with efficacy demonstrated at 24 hours. This approval represents an exciting new option
in ocular allergy itch relief therapy.”
1/3
Pazeo solution is anticipated to be available by prescription in the United States in March
2015, followed by Latin American and Asian markets through 2017.
About Allergic Conjunctivitis
Allergic conjunctivitis is more commonly referred to as eye allergies and affects the
conjunctiva, which is the clear layer of skin overlying the eyes. Eye allergies are not
typically harmful to a person's eyes or vision; however, they can cause discomfort. The
most common subtypes of allergic conjunctivitis are seasonal allergic conjunctivitis,
which lasts for a short period of time, and perennial allergic conjunctivitis, a chronic, yearround condition.2
Important Safety Information About Pazeo (olopatadine hydrochloride ophthalmic
solution) 0.7%
As with any eye drop, care should be taken not to touch the eyelids or surrounding areas
with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep
bottle tightly closed when not in use.
Patients should not wear a contact lens if their eye is red. The preservative in Pazeo
solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients
should be instructed to wait at least five minutes after instilling Pazeo solution before they
insert their contact lenses. For additional information about Pazeo solution, please refer
to the full prescribing information.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such
as “will,” “can,” “anticipated,” or similar terms, or by express or implied discussions regarding
potential future marketing approvals for Pazeo, or regarding potential future revenues from Pazeo.
You should not place undue reliance on these statements. Such forward-looking statements are
based on the current beliefs and expectations of management regarding future events, and are
subject to significant known and unknown risks and uncertainties. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements. There can be no
guarantee that Pazeo will be submitted or approved for sale in any additional markets, or at any
particular time. Nor can there be any guarantee that Pazeo will be commercially successful in the
future. In particular, management’s expectations regarding Pazeo could be affected by, among
other things, the uncertainties inherent in research and development, including unexpected clinical
trial results and additional analysis of existing clinical data; unexpected regulatory actions or
delays or government regulation generally; the company’s ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected manufacturing
issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the
US Securities and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and
societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet
these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive
vaccines and over-the-counter products. Novartis is the only global company with leading positions
in these areas. In 2014, the Group achieved net sales of USD 58 billion, while R&D throughout the
Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 130,000 full-timeequivalent associates and sell products in more than 180 countries around the world. For more
information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
*Pataday® (olopatadine hydrochloride ophthalmic solution) 0.2%, a prescription product marketed by Alcon, is used to treat
ocular itching associated with eye allergies.
2/3
References:
1. American College of Allergy, Asthma & Immunology, Allergy Facts. http://acaai.org/news/factsstatistics/allergies [Accessed December 10, 2014]
2. WebMD, Allergies Health Center. http://www.webmd.com/allergies/guide/eye-allergies-1 [Accessed
December 10, 2014]
###
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
[email protected]
Elizabeth Murphy
Novartis Alcon Communications
+ 1 817-551-8696 (direct)
+ 1 585-435-7379 (mobile)
[email protected]
e-mail: [email protected]
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
[email protected].
Novartis Investor Relations
Central phone:
Samir Shah
Pierre-Michel Bringer
Thomas Hungerbuehler
Isabella Zinck
+41 61 324 7944
+41 61 324 7944
+41 61 324 1065
+41 61 324 8425
+41 61 324 7188
e-mail: [email protected]
North America:
Richard Pulik
Susan Donofrio
+1 212 830 2448
+1 862 778 9257
e-mail: [email protected]
3/3